Clinical Trials on Hereditary Breast/Ovarian Cancer (brca1, brca2) in New Zealand
Total 195 results
-
Weill Medical College of Cornell UniversityCompletedBreast Cancer | Gynecologic Cancer | BRCA1 Mutation | BRCA2 MutationUnited States
-
The National Institute of LymphologyThe DrMarga Practice Group; The Center for Restorative Breast Surgery, LLCUnknownBreast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Congenital Lymphedema | Acquired LymphedemaUnited States
-
NYU Langone HealthWithdrawnBreast Cancer | BRCA1 Mutation | BRCA2 MutationUnited States
-
Columbia UniversityAmerican Cancer Society, Inc.CompletedBreast Cancer | Ovarian Cancer | BRCA1 Mutation | BRCA2 MutationUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBreast Cancer | brca1 Mutation Carrier | brca2 Mutation CarrierUnited States
-
Dana-Farber Cancer InstituteJohns Hopkins University; GlaxoSmithKline; Translational Breast Cancer Research...RecruitingBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer | Deleterious PALB2 Gene Mutation | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene MutationUnited States
-
Beth Israel Deaconess Medical CenterJohns Hopkins University; Dana-Farber Cancer Institute; AstraZenecaActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)United States
-
Tango Therapeutics, Inc.RecruitingBreast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | BRCA1 Mutation | BRCA-Mutated Ovarian Carcinoma | BRCA-Associated Breast Carcinoma | HRD Positive Advanced Ovarian CancerUnited States
-
Rana McKay, MDUniversity of California, San Diego; AstraZenecaRecruitingProstate Cancer | BRCA1 Mutation | BRCA2 Mutation | Prostatic Adenocarcinoma | High-Risk CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Ovarian Carcinoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditionsUnited States
-
Tesaro, Inc.European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaboratorsTerminatedOvarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of BreastUnited States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial TumorUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedStage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.Active, not recruitingBreast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene MutationItaly, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
-
VA Office of Research and DevelopmentRecruitingMetastatic Castrate Resistant Prostate Cancer | BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 | RAD51B, RAD51C, RAD51D, or RAD54L MutationsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Austrian Breast & Colorectal Cancer Study...RecruitingNeoplasms | Breast Cancer | Breast Neoplasms | Breast Diseases | Breast Carcinoma | BRCA1 MutationUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHereditary Breast and Ovarian Cancer Syndrome | Premenopausal | Deleterious BARD1 Gene Mutation | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Deleterious BRIP1 Gene Mutation | Deleterious EPCAM Gene Mutation | Deleterious MLH1 Gene Mutation | Deleterious MSH2 Gene Mutation | Deleterious... and other conditionsUnited States
-
Roswell Park Cancer InstituteAstraZenecaActive, not recruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous AdenocarcinomaUnited States
-
General Oncology, Inc.Myriad Genetics, Inc.RecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
NYU Langone HealthRecruitingMLH1 Gene Mutation | RAD51C Gene Mutation | BRIP1 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | BRCA-Mutated Ovarian Carcinoma | MSH2 A636P | EPCAMUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingDuctal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in SituUnited States
-
PfizerMedivation, Inc.; Myriad Genetic Laboratories, Inc.TerminatedBreast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene MutationUnited States, Spain, United Kingdom, Germany, France
-
PfizerMedivation, Inc.CompletedBreast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene MutationKorea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingScreening Breast MRI in Patients Who Are BRCA Mutation CarriersUnited States
-
AstraZenecaCompletedRelapsed Ovarian Cancer, BRCA Mutation, Platinum SensitivityUnited States, Canada
-
AstraZenecaRecruitingAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerSpain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOsteoporosis | Ovarian Carcinoma | Hereditary Breast and Ovarian Cancer SyndromeUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedFallopian Tube Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Female Reproductive CancerUnited States
-
Swedish Medical CenterGlaxoSmithKlineCompletedStage IV Breast Cancer | Stage IV Ovarian Cancer | Ovarian Epithelial Cancer Stage IIIUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.CompletedRelapsed Ovarian Cancer, BRCA Mutation, Platinum SensitivityUnited States, Italy, Spain, Belgium, Poland, Canada, Korea, Republic of, Brazil, Czechia, Hungary, Israel, Argentina, Mexico
-
amy tierstenAstraZeneca; Eisai Inc.CompletedRecurrent Ovarian Cancer | HER2-Negative Metastatic Breast CancerUnited States
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaCompleted
-
Memorial Sloan Kettering Cancer CenterCompleted
-
PfizerActive, not recruitingHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast CancerUnited States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
-
Tesaro, Inc.Merck Sharp & Dohme LLCCompletedNeoplasms | Breast Cancer | Advanced Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Peritoneal Cancer | Stage IV Breast CancerUnited States
-
Hoffmann-La RocheTerminatedTriple Negative Breast Cancer | Advanced Ovarian CancerUnited Kingdom, United States, Australia, Denmark, Canada
-
ExcellaBio LLCTerminatedGastric Cancer | Ovarian Cancer | Breast Cancer FemaleUnited States
-
VelosBio Inc.CompletedGastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditionsUnited States, Canada
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States, Colombia, Mexico, Chile
-
AstraZenecaMerck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.Active, not recruitingAdvanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum ChemotherapyKorea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
-
Leap Therapeutics, Inc.Pfizer; Merck KGaA, Darmstadt, GermanyTerminatedSolid Tumors | Advanced Triple Negative Breast Cancer | Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer | Advanced Metastatic Castration-Resistant Prostate Cancer | Advanced Platinum-Resistant Ovarian CancerUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditionsUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedTreating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer (BMS-247550)Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rutgers, The State University of New JerseyColorado Department of Public Health and Environment; University of New MexicoCompletedBreast Cancer | Ovarian CancerUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedVaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsSarcoma | Glioblastoma | Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Metastatic Renal Cell Cancer | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7 | Metastatic Breast Carcinoma | Metastatic BRCA-Associated Breast CarcinomaUnited States, Puerto Rico